SCHEMBL5437231

SCHEMBL5437231

N#Cc1c(-c2cccs2)ccn(CCCc2ccccc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 11/20 0.49
ALDH1A1 P00352 7/20 0.48
KDM4E B2RXH2 7/20 0.48
MAPK1 P28482 1/20 0.48
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PIM1 P11309 1/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5433914 0.85 GRM2 (0.49) GRM2ALDH1A1KDM4EMAPK1PIM1
SCHEMBL5442689 0.82 KDM4E (0.50) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5437256 0.79 GRM2 (0.67) GRM2
SCHEMBL5439783 0.77 KDM4E (0.61) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5435558 0.77 KDM4E (0.68) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5448963 0.76 ALDH1A1 (0.44) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5448961 0.76 ALDH1A1 (0.44) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5437018 0.76 GRM2 (0.50) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5437313 0.76 KDM4E (0.54) GRM2ALDH1A1KDM4EMAPK1POLB
SCHEMBL5448940 0.75 KDM4E (0.64) GRM2ALDH1A1KDM4EMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 GRM2 1/4885ALDH1A1 3403/4885KDM4E 1936/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 GRM2 1/4885ALDH1A1 2717/4885KDM4E 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.